Wide Ranks

BNR

Burning Rock Biotech Limited

5.30

Top Statistics
Market Cap 54 M Forward PE -9.15 Revenue Growth -7.30 %
Current Ratio 3.10 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -111.18 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.2690 Enterprise / Revenue 0.2350 Price To Sales Trailing12 Months 0.1068
Profitability
Profit Margins -111.18 % Operating Margins -82.06 %
Balance Sheet
Total Cash 532 M Total Cash Per Share 5.19 Total Debt 107 M
Total Debt To Equity 15.92 Current Ratio 3.10 Book Value Per Share 66.07
All Measures
Short Ratio 358.00 % Message Board Id finmb_309457193 Shares Short Prior Month 120297
Return On Equity -0.6889 City Guangzhou Uuid 20b4973b-d557-358c-9cbd-72e612a3f307
Previous Close 4.37 First Trade Date Epoch Utc 1 B Book Value 66.07
Beta 0.1450 Total Debt 107 M Volume 22766
Price To Book 0.0803 Last Split Date 1 B Fifty Two Week Low 2.62
Total Cash Per Share 5.19 Total Revenue 509 M Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -82.06 %
Net Income To Common -566780992 Implied Shares Outstanding 102 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 19370 Average Volume10days 19370
Total Cash 532 M Next Fiscal Year End 1 B Revenue Per Share 49.75
Held Percent Insiders 0.0004 Ebitda Margins -87.36 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 4.37
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.50
Open 4.08 Free Cashflow 7 M Dividend Yield 0.00 %
Return On Assets -0.3091 Time Zone Short Name EST Trailing Eps -7.63
Day Low 4.08 Address1 No. 5, Xingdao Ring Road North Shares Outstanding 8 M
Price Hint 2 Target High Price 0.0000 Website https://www.brbiotech.com
52 Week Change -0.3608 Average Volume 32828 Forward Eps -0.5800
Recommendation Key none Quick Ratio 272.00 % Last Split Factor 1:10
Regular Market Day High 5.41 Is_sp_500 False Profit Margins -111.18 %
Debt To Equity 15.92 Fifty Two Week High 9.99 Day High 5.41
Shares Short 80546 Regular Market Open 4.08 Industry Key diagnostics-research
Earnings Growth 0.00 % Enterprise To Revenue 0.2350 Revenue Growth -7.30 %
Shares Percent Shares Out 0.0079 Operating Cashflow -144480992 Currency USD
Time Zone Full Name America/New_York Market Cap 54 M Is_nasdaq_100 False
Zip 510005 Quote Type EQUITY Industry Diagnostics & Research
Long Name Burning Rock Biotech Limited Regular Market Day Low 4.08 Held Percent Institutions 0.6095
Current Price 5.30 Address2 International Bio Island Enterprise To Ebitda -0.2690
Financial Currency CNY Current Ratio 3.10 Gross Margins 67.70 %
Industry Disp Diagnostics & Research Country China Float Shares 55 M
Two Hundred Day Average 6.13 Enterprise Value 119 M Price To Sales Trailing12 Months 0.1068
Forward PE -9.15 Regular Market Volume 22766 Ebitda -445377504
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China.

It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.

The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC.

The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products.

In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model.

Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.

The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.